Michael Lehmann Appointed Patheon's President Of Global Pharmaceutical Development Services

TORONTO, Nov. 1, 2012 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that Michael Lehmann has joined the company as President of Global Pharmaceutical Development Services (PDS).

"I am pleased to be welcoming Mike and getting him quickly integrated with Patheon's leadership team," stated James C. Mullen, Patheon's Chief Executive Officer.  "He is a highly accomplished senior executive with a proven track record in the healthcare, life sciences and drug development sectors.  Patheon will significantly benefit from his recognized ability to drive both growth and competitiveness in varying market conditions, and I look forward to his future contributions as we continue to transform our business to provide the leading customer experience."

Mr. Lehmann was most recently Corporate Senior Vice President and General Manager of the Global Early Development business of Covance from 2005 to 2012, which is one of the world's largest drug development services companies.  In his role, he was responsible for global early development and P&L management; and key accomplishments included executive leadership in strategic deals between Covance, Lilly and Sanofi. Prior to joining Covance, Mr. Lehmann worked for 17 years at GE's Healthcare in key operational and management roles.  His career started with a focus in client services, managing large call centers for both external customers and repair technicians.  In 1998, he was tasked with assisting in the integration of the company's MECON acquisition, operational and clinical performance optimization services.  Mr. Lehmann progressed through various other comparable roles to emerge as the General Manager of the Multivendor Solutions business in 2003, where he was responsible for facilitating the upkeep and repair of other OEM diagnostic imaging equipment and accessories with complete P&L responsibilities.

1 2 Next › Last »